Tools
Upgrade to Pro 🌟

Upgrade for Pro stock ideas, Al signals, and more search.

Learn More

TCBP

TC BioPharm (Holdings) PLC Sponsored ADR · NASDAQ

Performance

-44.25%

1W

-87.55%

1M

-84.41%

3M

-94.42%

6M

-98.01%

YTD

-99.39%

1Y

Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Technical Analysis of TCBP 2024-11-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 60 suggests a bullish outlook. However, the overall Technical Score of 35 reinforces a bearish trend, indicating that despite some bullish signals from oscillators, the prevailing sentiment remains negative.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of TCBP

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.